AntibioticeBSE:ATB -1.37%74 Days Payable is 202.25 as of Mar. 2026, which is 53% above its 10-year median of 131.83. GuruFocus rates BSE:ATB with a GF Score™ of 74/100 and a GF Value™ of lei2.19 (Fairly Valued). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Antibiotice ranks better than 76.03% on this metric.
Antibiotice's average Accounts Payable for the
three
months ended in Mar. 2026 was lei96.2 Mil. Antibiotice's Cost of Goods Sold for the
three
months ended in Mar. 2026 was lei43.4 Mil.
Hence, Antibiotice's Days Payable for the
three
months ended in Mar. 2026 was 202.25.
The historical rank and industry rank for Antibiotice's Days Payable or its related term are showing as below:
BSE:ATB'
s Days Payable Range Over the Past 10 Years
Min: 91.6 Med: 131.83 Max: 161.15
Current: 154.36
During the past 13 years, Antibiotice's highest Days Payable was 161.15. The lowest was 91.60. And the median was 131.83.
BSE:ATB's Days Payable is ranked better than 76.03% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs BSE:ATB: 154.36
Antibiotice's Days Payable
increased
from Mar. 2025 (178.54) to Mar. 2026 (202.25).
It may suggest that Antibioticedelayed paying its suppliers.
Antibiotice Days Payable Related Terms
Antibiotice Days Payable Historical Data
* Premium members only.
The historical data trend for Antibiotice's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSE:ATB vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Antibiotice's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Antibiotice Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Antibiotice's Days Payable distribution charts can be found below:
* The bar in red indicates where Antibiotice's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Antibiotice's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Antibiotice (BSE:ATB) has a Days Payable of 202.25 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Antibiotice and its competitors. This is 53% above median its historical median of 131.83. Over the past decade, Antibiotice's Days Payable has ranged from 91.60 to 161.15. According to the industry distribution chart, Antibiotice ranks #221 out of 922 companies in the Drug Manufacturers industry, placing it in the top 24%.
Is Antibiotice's Days Payable too high?
Antibiotice's current Days Payable of 202.25 is 53% above median its 10-year median of 131.83. Over the past 10 years, this metric has ranged from a low of 91.60 to a high of 161.15. The Drug Manufacturers industry median Days Payable is 90.84. Antibiotice's value of 202.25 is 122.7% above this industry median. Based on the distribution chart, Antibiotice ranks #221 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Antibiotice has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Antibiotice's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Antibiotice ranks #221 out of 922 companies for Days Payable. This places Antibiotice in the top 24% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. Antibiotice's value of 202.25 is 122.7% above this benchmark. Historically, Antibiotice's own Days Payable has ranged from 91.60 to 161.15 over the past decade. While the company's 10-year median is 131.83 vs. the industry median of 90.84, Antibiotice has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Antibiotice's current Days Payable of 202.25 is 122.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Antibiotice and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Antibiotice's current Days Payable is 202.25, which is 53% above median its own 10-year median of 131.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antibiotice stock overvalued right now?
Based on GuruFocus' analysis, Antibiotice (BSE:ATB) is currently considered Fairly Valued. The stock's GF Value™ is lei2.19, compared to a current price of lei2.16 — trading 1.4% below its estimated fair value. The current Days Payable is 202.25, which is 53% above median its 10-year median of 131.83 and 122.7% above the Drug Manufacturers industry median of 90.84. Antibiotice's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Antibiotice (BSE:ATB), the current Days Payable is 202.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Antibiotice (BSE:ATB) Overvalued in 2026?
Based on GuruFocus' analysis, Antibiotice stock appears to be undervalued.
The current stock price of lei2.16 is trading 1.4% below its estimated GF Value™ of lei2.19.
GuruFocus considers Antibiotice to be Fairly Valued.
Key valuation signals for BSE:ATB:
Days Payable: 202.25 (53% above median its 10-year median of 131.83)
GF Value™: lei2.19 vs. price of lei2.16 (1.4% below fair value)
Industry Position: 122.7% above the Drug Manufacturers median (#221 of 922)
No single metric tells the full story. See the BSE:ATB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Antibiotice SA is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).
74GF Score
Get the complete analysis for BSE:ATB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:ATB has been successfully added to your 
